New Launch3 Feb 2026, 10:40 am
Wanbury Achieves First Sales Invoicing and Commercial Shipment Milestone for High-Demand Anaesthetic API
AI Summary
Wanbury Limited, a leading player in Active Pharmaceutical Ingredients (APIs), and branded formulations, has achieved a significant milestone. The company has confirmed first sales, customer invoicing, and commercial shipment to a European customer for its newly commercialized anaesthetic API from its cutting-edge Tanuku facility. This achievement validates global demand and signals rapid growth ahead.
Key Highlights
- Wanbury has secured orders and completed invoicing and product shipment for its new anaesthetic API.
- The company's Tanuku facility has been instrumental in this achievement.
- Wanbury is set to ramp up production capacity at Tanuku, indicating expansion and growth.
- The company has a strong presence in the API global market and domestic branded Formulation.
- Wanbury's API product portfolio includes Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine, and Ketamine Hydrochloride.